A groundbreaking first-in-human clinical trial has demonstrated that gene therapy can safely and effectively treat homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder characterized by dangerously elevated cholesterol levels from birth. The phase 1 study, published in Nature Medicine, enrolled three adult patients who received AAV8-mediated LDL receptor gene therapy—a revolutionary approach that addresses the genetic root cause rather than merely managing symptoms. Researchers delivered functional copies of the LDL receptor gene directly to liver cells, enabling improved cholesterol metabolism. All three participants showed encouraging early safety and efficacy signals with no serious adverse events reported during the initial observation period. This landmark trial represents a paradigm shift in treating genetic disorders, moving beyond conventional therapies that focus on symptom control toward interventions that correct underlying genetic defects.
Was this article helpful?
